MedTrace Logo

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

NCT01221571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2013-06-26

No results posted yet for this study

Summary

The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.

Conditions

Interventions

DRUG

AFM 13

Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.

Sponsors & Collaborators

  • Affimed GmbH

    lead INDUSTRY

Principal Investigators

  • Andreas Engert, Professor · University Hospital Cologne, Germany

  • Anas Younes, Professor · MD Anderson Cancer Center, Houston, Texas

  • Max S Topp, Professor · University Hospital Würzburg, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-05-31
Completion
2013-06-30

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01221571 on ClinicalTrials.gov